Literature DB >> 27783475

Cancer Patients? Willingness to Routinely Complete the EQ-5D Instrument at Clinic Visits.

Hiten Naik1, Xin Qiu2, M Catherine Brown1, Mary Mahler1, Henrique Hon1, Kyoko Tiessen1, Henry Thai1, Valerie Ho1, Christina Gonos1, Rebecca Charow1, Vivien Pat1, Margaret Irwin1, Lindsay Herzog1, Anthea Ho1, Wei Xu2, Doris Howell1, Soo Jin Seung3, Geoffrey Liu1, Nicole Mittmann3,4,5.   

Abstract

BACKGROUND: Health utility (HU) scores play an essential role in pharmacoeconomic analyses. Routine clinical administration of the EuroQol-5 Dimensions (EQ-5D) can allow for HU and health related quality of life (HRQOL) assessments in the real-world setting.
OBJECTIVES: The primary goals of this study were to evaluate whether patients were willing to complete the EQ-5D instrument on a routine basis and which clinical or demographic factors influence this willingness.
METHODS: 618 adult cancer survivors across multiple cancer disease sites at the Princess Margaret Cancer Centre completed an acceptability survey after completing the EQ-5D instrument.
RESULTS: The mean (SD) EQ-5D score was 0.81 (0.15). Among those surveyed, 88% reported that the EQ-5D was easy to complete. 91% took under 5 minutes and 88% were satisfied with its length. 85% were satisfied with the types of questions asked on the EQ-5D. Importantly, 92% reported that they would complete the EQ-5D, even if it were used solely for research purposes; 73% agreed with the notion of completing it regularly at their clinic visits. Patients with lower EQ-5D scores (p=0.0006), and non-Caucasians (p=0.0024; 60% willing) were less willing to complete the instrument on a regular basis. Curability of tumour, disease site, age, and gender did not influence willingness.
CONCLUSIONS: The majority of cancer patients across disease sites are willing to complete the EQ-5D instrument regularly, even if it were solely for research purposes, but up to 39% declined participation in the first place.

Entities:  

Keywords:  EQ-5D; cancer; ethnicity; health utilities; policy; quality of life

Mesh:

Year:  2016        PMID: 27783475     DOI: 10.22374/1710-6222.23.1.1

Source DB:  PubMed          Journal:  J Popul Ther Clin Pharmacol        ISSN: 2561-8741


  1 in total

1.  Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites.

Authors:  M Moskovitz; K Jao; J Su; M C Brown; H Naik; L Eng; T Wang; J Kuo; Y Leung; W Xu; N Mittmann; L Moody; L Barbera; G Devins; M Li; D Howell; G Liu
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.